- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00413439
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
May 9, 2023 updated by: Basilea Pharmaceutica
Open Label, Multi-center, Sequential Group Clinical Study to Determine the Safety and Efficacy of Escalating Dosing Regimens of Intravenous BAL8557 in the Prophylaxis of Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Patients who undergo chemotherapy for leukemia will receive study medication for prevention of fungal infections.
The study investigates the safety and tolerability of two different dosages, the efficacy in prevention of fungal diseases.
Study Overview
Detailed Description
Patients with Acute Myeloid Leukemia who undergo aggressive chemotherapy are due to immunosuppression susceptible to infections, including fungal infections.
As the failure rate in the treatment of invasive fungal infections is high, prophylaxis is frequently recommended.
This open label study investigates the safety and tolerability of two different dosages of a water soluble azole antifungal, as well as the efficacy in prevention of invasive fungal infections and pharmacokinetic data.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bremen, Germany
-
Cologne, Germany, 50937
- University Cologne
-
Frankfurt, Germany
-
Mainz, Germany
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- diagnosis of acute myeloid leukemia
- patients entering first induction treatment; or subsequent chemotherapy if no prior invasive fungal infection was observed
- expected to be neutropenic for >9 and <28 days after enrollment
- women of childbearing potential must have a negative pregnancy test
Exclusion Criteria:
- patients who received any systemic antifungal therapy for more than 72 hours prior to first administration of study medication. Topical polyenes or nystatin are acceptable but should be discontinued during the study
- patients who received systemic antifungal therapy for proven or probable fungal infection in the last 12 months
- patients with fever defined as central body temperature of > 38°C
- known hypersensitivity to azoles or any component of the study medication
- concomitant use of rifampicin, rifabutin, ergots alkaloids, terfenadine, astemizole, cisapride, pimozide, quinidine, long acting barbiturates, neostigmine, and carbamazepine
- hepatic or severe renal dysfunction
- patients with a medical history of oliguria unresponsive to fluid challenge
- patients with a concomitant medical condition that may be an unacceptable additional risk to the patient should he/she participate in the study
- treatment with any investigational drug within 30 days prior to the first administration of study medication except open label chemotherapy protocols
- suspected other or additional cause for neutropenia or immunosuppression
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose isavuconazole intravenous solution
|
Intravenous solution or oral capsules
Other Names:
|
Experimental: High dose isavuconazole intravenous solution or oral capsules
|
Intravenous solution or oral capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessed by the recording of adverse events, laboratory tests, and electrocardiograms (ECGs)
Time Frame: Up to Day 28
|
Up to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy assessed by the frequency of invasive fungal infections
Time Frame: Up to Day 28
|
Up to Day 28
|
Pharmacokinetics: drug plasma levels
Time Frame: Up to Day 28
|
Up to Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Oliver Cornely, MD, University of Cologne
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
December 18, 2006
First Submitted That Met QC Criteria
December 18, 2006
First Posted (Estimate)
December 19, 2006
Study Record Updates
Last Update Posted (Actual)
May 10, 2023
Last Update Submitted That Met QC Criteria
May 9, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WSA-CS-002
- 2005-005294-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Isavuconazole
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Renal ImpairedUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Safety and Tolerability in ElderlyUnited States
-
Astellas Pharma IncBasilea Pharmaceutica International LtdCompletedInvasive Fungal Infections | AspergillosisKorea, Republic of, United States, Belgium, Israel, Mexico, Canada, Brazil, Chile, Argentina, France, Thailand, Egypt, Australia, Germany, India, Lebanon, Poland, Russian Federation, South Africa
-
Astellas Pharma IncBasilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of BAL4815 | Pharmacokinetics of BAL8728China
-
PfizerCompletedMucormycosis | Invasive AspergillosisSpain, Germany, France, United Kingdom, Italy
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MetforminUnited States
-
PfizerRecruitingInvasive Fungal DiseaseChina
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Plasma Mycophenolic Acid (MPA) | Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)United States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of SirolimusUnited States
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.CompletedHematologic Malignancy | Myeloproliferative DisorderUnited States